(Q36694110)

English

Isolation and characterisation of a human anti-idiotypic scFv used as a surrogate tumour antigen to elicit an anti-HER-2/neu humoral response in mice

scientific article published on May 2004

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Isolation and characterisation of a human anti-idiotypic scFv used as a surrogate tumour antigen to elicit an anti-HER-2/neu humoral response in mice (English)

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

author name string

M Coelho

1

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

P Gauthier

2

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

M Pugnière

3

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

F Roquet

4

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

A Pèlegrin

5

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

I Navarro-Teulon

6

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

language of work or name

0 references

publication date

1 May 2004

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

90

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

10

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

2032-2041

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Selection of large diversities of antiidiotypic antibody fragments by phage display

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409470

30 September 2017

Mechanism of action of anti-HER2 monoclonal antibodies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409470

30 September 2017

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409470

30 September 2017

The use of phage display for the development of tumour targeting agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409470

30 September 2017

Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409470

30 September 2017

Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409470

30 September 2017

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409470

30 September 2017

Antigen mimicry by an anti-idiotypic antibody single chain variable fragment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409470

30 September 2017

Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409470

30 September 2017

Making antibodies by phage display technology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409470

30 September 2017

Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409470

30 September 2017

Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409470

30 September 2017

Towards a network theory of the immune system.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409470

30 September 2017

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409470

30 September 2017

Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409470

30 September 2017

Suppression of in vivo tumor formation induced by simian virus 40-transformed cells in mice receiving antiidiotypic antibodies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409470

30 September 2017

Active specific immunotherapy in patients with melanoma. A clinical trial with mouse antiidiotypic monoclonal antibodies elicited with syngeneic anti-high-molecular-weight-melanoma-associated antigen monoclonal antibodies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409470

30 September 2017

Anti-Idiotype Monoclonal Antibodies as Vaccines for Human Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409470

30 September 2017

Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409470

30 September 2017

Prognostic significance of her-2/neu expression in breast cancer and its relationship to other prognostic factors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409470

30 September 2017

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409470

28 June 2018

Neonatal mouse immunity against group B streptococcal infection by maternal vaccination with recombinant anti-idiotypes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409470

28 June 2018

Human HER-2/neu protein immunization circumvents tolerance to rat neu: a vaccine strategy for 'self' tumour antigens

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409470

28 June 2018

Immunization with phage-displayed mimotopes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409470

28 June 2018

The neu oncogene encodes an epidermal growth factor receptor-related protein

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409470

28 June 2018

Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409470

28 June 2018

Vaccination with cytoplasmic ErbB-2 DNA protects mice from mammary tumor growth without anti-ErbB-2 antibody

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409470

5 September 2018

Inhibition of mammary carcinogenesis by systemic interleukin 12 or p185neu DNA vaccination in Her-2/neu transgenic BALB/c mice.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409470

5 September 2018

Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409470

5 September 2018

Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409470

5 September 2018

Induction of anti-self-immunity to cure cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409470

5 September 2018

Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409470

5 September 2018

Activity of a single-chain immunotoxin that selectively kills lymphoma and other B-lineage cells expressing the CD40 antigen

1 reference

https://pubmed.ncbi.nlm.nih.gov/15138490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Autoantibody to p185erbB2/neu oncoprotein by vaccination with xenogenic DNA

1 reference

https://pubmed.ncbi.nlm.nih.gov/15138490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vaccination with syngeneic monoclonal anti-idiotype protects against a tumour challenge

1 reference

https://pubmed.ncbi.nlm.nih.gov/15138490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunotherapy of murine sarcomas with auto-anti-idiotypic monoclonal antibodies which bind to tumor-specific T cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/15138490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Idiotype vaccines against human T cell leukemia. II. Generation and characterization of a monoclonal idiotype cascade (Ab1, Ab2, and Ab3)

1 reference

https://pubmed.ncbi.nlm.nih.gov/15138490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/15138490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Purification of bacterially expressed single chain Fv antibodies for clinical applications using metal chelate chromatography

1 reference

https://pubmed.ncbi.nlm.nih.gov/15138490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Murine monoclonal anti-idiotypic antibody as a surrogate antigen for human Her-2/neu

1 reference

https://pubmed.ncbi.nlm.nih.gov/15138490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines

1 reference

https://pubmed.ncbi.nlm.nih.gov/15138490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Murine dendritic cells pulsed with an anti-idiotype antibody induce antigen-specific protective antitumor immunity

1 reference

https://pubmed.ncbi.nlm.nih.gov/15138490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/15138490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/SJ.BJC.6601825

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36694110&oldid=2199195588"